BPC-157: Evidence, Legal Status & Verified Clinics

BPC-157 is a research peptide studied mostly in animal models for tissue and gut repair. See what the evidence and 2026 UK & US legal status actually say, and what to ask clinics that reference it. This page is informational and does not diagnose, prescribe, or recommend therapies.

Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.

Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.

Common contexts

Commonly referenced in recovery-oriented clinic discussions.
Often listed alongside broader rehabilitation support programs.
Clinics may position it within injury recovery, gut health, or tissue repair conversations.

Safety information

Suitability varies by personal medical history and jurisdiction.
Request clear clinician oversight and monitoring protocols before booking.
Ask clinics to explain the evidence base and sourcing standards before treatment is discussed.

Quick summary

BPC-157 is a synthetic peptide based on a sequence found in human gastric (stomach) juice, studied mainly in animal and laboratory research for tissue and gut repair.
It is not an approved medicine. The UK's MHRA treats it as an unlicensed substance, and in the US it remains unapproved and under regulatory review.
Most published evidence is preclinical (animal and cell studies); robust human clinical-trial data is still lacking, so proven benefits in people should not be assumed.
Clinics that reference BPC-157 usually do so within recovery, injury-support, or gut-health discussions, often alongside TB-500.
Because it sits in a regulatory grey area with an unregulated supply chain, the most important things to compare are clinician oversight, sourcing transparency, and how honestly a provider explains the evidence.
This page is informational only — it does not diagnose, prescribe, recommend BPC-157, or provide dosing guidance.

Evidence at a glance

A scannable summary of what the current research and UK/US regulatory position actually show. Educational only — not medical advice, and no dosing guidance.

Evidence: Preclinical only — most research is animal and cell studies. Robust human clinical-trial evidence is lacking, so benefits in people should not be assumed.
Human data: Insufficient. No large human trials establishing efficacy or long-term safety.
UK regulatory status: Not a licensed UK medicine. The MHRA treats it as an unlicensed substance that cannot be marketed or supplied for human use; it is sold only as a 'research chemical' not intended for human consumption.
US regulatory status: Not FDA-approved. Removed from the FDA's 503A restricted compounding list in April 2026, and in July 2026 the FDA's compounding advisory committee (PCAC) voted to recommend adding BPC-157 to the 503A bulks list — a nonbinding recommendation with no final FDA determination yet, and not approval.
Anti-doping (sport): Because it is not approved for human use, BPC-157 falls under WADA's S0 (non-approved substances) category and is prohibited in sport at all times. Strict liability applies to athletes.

Last reviewed 10 August 2026. Regulatory status can change — always confirm the current position with a qualified clinician.

Claim vs evidence

Common marketing and internet claims about BPC-157, set against what the research actually shows. Educational only — not medical advice.

Claim	Human evidence	What the evidence shows
“Heals tendon and ligament injuries”	No human trials	Animal studies suggest effects on tendon and soft-tissue repair, but robust human trials are lacking — a proven injury-healing benefit in people should not be assumed.
“Repairs the gut and reverses IBD”	No human trials	Animal models show gastrointestinal effects; human evidence for treating IBD or “leaky gut” is not established.
“Safe, with no side effects”	Not established	Long-term human safety has not been established in trials, and product quality varies widely across an unregulated supply chain.
“Pharma-grade and clinically proven”	No approval	BPC-157 has no MHRA marketing authorisation; grey-market product is not independently verified for identity or purity.
“Used by elite athletes for faster recovery”	Banned in sport	BPC-157 falls under WADA's S0 (non-approved substances) category — athletes face strict-liability anti-doping risk regardless of how it is marketed.

Clear intro

BPC-157 users are often still evaluating whether a clinic's recovery language is credible. The key comparison is usually not just BPC-157 itself, but whether the provider can explain evidence limits, regulatory status, rationale, and supervision clearly.

Who this is for

This page is useful for patients researching recovery-oriented, rehabilitation, or regenerative medicine clinics that reference BPC-157 within a broader plan rather than as a standalone promise.

What to ask before choosing a clinic

Why is BPC-157 being discussed for my goal specifically?
What evidence and safety limits should I understand first?
What monitoring or follow-up is built into the protocol?

Pricing and red flags

BPC-157 pricing is often bundled into broader recovery or regenerative pathways, so the headline number matters less than the level of clinician involvement and follow-up.

Guaranteed tissue-repair or injury-recovery claims.
No explanation of evidence quality, regulatory status, or sourcing.
No medical assessment before protocol discussion.

What is BPC-157?

BPC-157 (sometimes called 'Body Protection Compound-157') is a synthetic peptide built from a 15-amino-acid sequence derived from a protein found in human gastric juice. It is not a licensed medicine. In the United Kingdom the MHRA treats BPC-157 as an unlicensed substance that cannot be marketed or supplied for human use, and it is generally sold only as a 'research chemical' not intended for human consumption. In the United States it is not FDA-approved: it had been placed in the FDA's restricted 503A bulk-compounding category and was removed from that restricted list in April 2026 as part of a procedural review reset, with a federal advisory committee due to reassess it in mid-2026. Removal from the restricted list is not the same as approval. On clinic directories it usually appears in recovery, rehabilitation, and gut-health contexts rather than as a mainstream prescription treatment.

How it works

In laboratory and animal studies, BPC-157 has been investigated for effects on blood-vessel formation, tendon and ligament cells, and the gut lining, and researchers have explored signalling pathways linked to tissue repair. It is important to be clear that these findings come largely from preclinical (animal and cell) models, and that a described mechanism is not the same as a proven result in people. For someone comparing clinics, what matters more than mechanism language is whether a provider can honestly explain the limits of the human evidence and why they are discussing BPC-157 for a specific goal.

Typical use cases

Recovery and rehabilitation clinics that discuss soft-tissue, tendon, or ligament support, usually as one part of a wider plan rather than a standalone fix.
Gut-health and functional-medicine settings, reflecting the peptide's origins in gastric research.
Performance and longevity providers who reference it alongside TB-500 — though overlapping mechanisms do not mean it is appropriate for everyone.

Cost overview

BPC-157 is rarely priced as a standalone product; it is usually bundled into a broader recovery, regenerative, or functional-medicine programme. That makes the headline figure less useful than understanding what clinician involvement, monitoring, and follow-up are included. Because the supply chain is largely unregulated, sourcing transparency matters as much as price. See the peptide therapy cost guide.

What to expect from clinics

A credible clinic should be upfront that BPC-157 is not a licensed medicine and that most evidence is preclinical, rather than implying proven results.
Expect a proper assessment of your history and goals, plus a clear explanation of sourcing, supervision, and follow-up before any protocol is discussed.
Be cautious if a provider cannot explain the regulatory status or treats BPC-157 as a routine, risk-free add-on.

Safety considerations

Because BPC-157 is not an approved medicine, its long-term safety in humans has not been established through large clinical trials, and product quality varies widely across an unregulated supply chain. Anyone considering it should do so only in discussion with a licensed clinician who can explain the evidence limits, regulatory status, and possible risks for their individual situation. This page does not recommend BPC-157 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.

Frequently asked questions about BPC-157

Is BPC-157 legal in the UK?

BPC-157 is not licensed as a medicine in the UK. The MHRA treats it as an unlicensed substance, so it cannot legally be marketed or supplied for human use, although it is sold as a 'research chemical' not intended for human consumption. It is not a controlled drug under the Misuse of Drugs Act.

Is BPC-157 FDA-approved in the US?

No. BPC-157 is not FDA-approved. It had been placed in a restricted compounding category and was removed from that restricted list in April 2026 as part of a procedural review reset — but removal is not approval. It remains an unapproved, investigational substance. On 23 July 2026 an FDA advisory committee voted to recommend adding BPC-157, KPV, TB-500 and MOTS-c to the 503A compounding list, against the recommendation of the FDA's own staff scientists. The FDA has not made a final determination, and an advisory recommendation is not the same as FDA approval.

What is the evidence behind BPC-157?

Most published research on BPC-157 comes from animal and laboratory studies looking at tissue and gut repair. High-quality human clinical trials are still lacking, so claims of proven benefits in people should be treated with caution.

Why do some clinics offer BPC-157 if it isn't approved?

Some recovery, regenerative, and functional-medicine clinics reference BPC-157 within broader programmes, operating in a regulatory grey area. Because of that, it is especially important to look for transparent clinician oversight, honest discussion of the evidence, and clear sourcing.

Is BPC-157 the same as TB-500?

No. They are different peptides, though they are often discussed together in recovery contexts. If you are comparing them, see our BPC-157 vs TB-500 comparison.

Does Peptide Clinic Finder sell or recommend BPC-157?

No. Peptide Clinic Finder is an informational directory. We do not sell BPC-157, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.

Related comparisons: BPC-157 vs TB-500, BPC-157 vs GHK-Cu, BPC-157 vs Ipamorelin.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Compare Providers Get Matched Browse city clinics

Related BPC-157 pages

Move from peptide research into clinic comparisons, guides, and matching.

Compare BPC-157 clinics (UK)Is BPC-157 legal in the UK & Ireland?Find peptide clinics near you BPC-157 vs TB-500 BPC-157 vs GHK-Cu BPC-157 vs Ipamorelin The Catalyst Clinic LiveNow Longevity Menon Health Nūūtro Extend Medical HUM2N

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering BPC-157

RecommendedVerified

The Catalyst Clinic

London, United Kingdom5.0

Doctor-led peptide advisory consultations in central London. Every protocol is built around comprehensive bloodwork and personally led by Dr Ethan Hausman-Marquis, who reports a PhD from the Karolinska Institute, with compounds sourced from GMP-certified, EMA-regulated pharmacies.

Google 5.0 (48)

Doctor-led clinical governance

Peptide Therapy Regenerative Medicine Longevity

From £600